Darunavir

Medical Advocates
Ethics and Infectious Diseases

Ethical Challenges

Screening/Testing
Refusal of Care/Services
Detention
Patient Exploitation
Compulsory Treatment
Decision-Making
Reproduction
Transplants
End-of-Life Care
Enteral Nutrition
Professional Associations

National Challenges         Sterilization
Bioterrorism                     Prison Challenges
HIV Exceptionalism           Conflicts of Interest
Pharmaceutical Industry   Pregnancy
HIV Prevention
Stigma
Physician Reimbursement
Ethics and Disease Challenges and Duties
HIV Cure
Ebola Virus Disease
Executions

Ethics Main Page Main New and Noteworthy Home Page

Medical Advocates
Darunavir(Prezista/TMC-114)

Conference Archives – A

IDSA – 2007
47th ICAAC
11th European AIDS Conference
American Conference on HIV Treatment-2007
5th European HIV Drug Resistance Conference
2007 ASCPT Annual Meeting
4th IAS Conference

Conference Archives – B

Conferences Main Page Main New and Noteworthy Home Page

Last Update: September 11, 2008

Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Pediatric data are indexed in the pediatric section

IDSA 2007

POWERPOINT PRESENTATION
Influence of Baseline Factors on Virologic Response to PREZISTA/Ritonavir (PREZISTA/r)
vs Lopinavir/r (LPV/r): Week 48 Outcome in TITAN
WD Hardy, M D Berger, E De Paepe, et al
Presentation

47th ICAAC

POSTER
Development of resistance in patients with virologic failure (VF) on darunavir/ritonavir (DRV/r)
or lopinavir/ritonavir (LPV/r): results of a randomized, controlled, Phase III trial in
treatment-experienced patients (TITAN)
S De Meyer, E De Paepe, T Vangeneugden, et al
PDF Poster

POWERPOINT PRESENTATION
Efficacy and Safety of Darunavir/ritonavir versus Lopinavir/ritonavir in ARV
Treatment-Naïve HIV-1-Infected Patients at Week 48: ARTEMIS (TMC114-C211)
DeJesus E, Ortiz R, Khanlou H, et al
Presentation

11th European AIDS Conference

POWERPOINT PRESENTATION
ARTEMIS: Efficacy and safety of lopinavir (BID vs QD) and darunavir (QD) in
antiretroviral-naïve patients.
N Clumeck, J Van Lunzen, P Chiliade, et al
Presentation

POWERPOINT PRESENTATION
Effect of extrinsic and intrinsic factors on the pharmacokinetics of darunavir/ritonavir (DRV/r) in HIV-1 patients:
results of a randomised, controlled, Phase III study (TITAN)
VJ Sekar, E De Paepe, B Van Baelen, et al
Presentation

POSTER
Tolerability of darunavir/r versus lopinavir/r in lopinavir/r-naïve, treatment-experienced, hepatitis B and/or
C co-infected patients in TITAN
Bánhegyi D, Suter F, De Paepe E, et al
PDF Poster

POSTER
Pharmacokinetic/pharmacodynamic (PK/PD) analyses of darunavir in the TITAN study
Sekar V, De Paepe E, Van Baelen B, et al
PDF Poster

POSTER
Lower virological failure (VF) rate and mutations development during treatment with
darunavir/ritonavir (DRV/r) compared with lopinavir/ritonavir (LPV/r) in treatment-experienced
patients: TITAN 48-week resistance analysis
De Meyer S, De Paepe E, Vangeneugden T, et al
PDF Poster

POSTER
Efficacy of darunavir/ritonavir in treatment-experienced HIV-1-infected patients at 96 weeks in the
POWER 1 and 2 trials
Pozniak A, Jayaweera D, Hoy J, et al
PDF Poster

POSTER
Safety and tolerability of darunavir/ritonavir in treatment-experiencedHIV-1-infected patients at 96
weeks in the POWER 1, 2 and 3 trials
Yeni P, Roberts A, Van Baelen B, et al
PDF Poster

POSTER
Effect of baseline factors on virological response to darunavir/r and lopinavir/r at Week 48 in TITAN
Berger DS, Northland R, Scribner A, et al
PDF Poster

American Society for Clinical Pharmacology and
Therapeutics 2007 Annual Meeting

POSTER
Effect of the HIV protease inhibitor darunavir (TMC114), coadministered with low-dose ritonavir,
on the pharmacokinetics of digoxin in healthy volunteers
Sekar V, El Malt M, De Paepe E, et al
PDF Poster

5th European HIV Drug Resistance Workshop

POSTER
Darunavir Exhibits High Levels of In Vitro Antiviral Activity against Clinical
Samples with Different Levels of Susceptibility to Atazanavir/Ritonavir
M-P de Béthune; L Bacheler; S De Meyer, et al
PDF Poster
POSTER
Efficacy of darunavir (DRV)/r 800/100mg qd in patients with low DRV resistance
S De Meyer, S Spinosa-Guzman, T Vangeneugden, et al
PDF Poster

47th ICAAC

POWERPOINT PRESENTATION
Efficacy and Safety of Darunavir/ritonavir versus Lopinavir/ritonavir in ARV Treatment-
Naïve HIV-1-Infected Patients at Week 48: ARTEMIS (TMC114-C211)
DeJesus E, Ortiz R, Khanlou H, et al
Presentation

The American Conference for the Treatment of HIV- 2007

POSTER
Darunavir Resistance–Associated Mutations: Prevalence in Samples Received for Routine Clinical
Resistance Testing
AR Rinehart; M-P de Béthune. G Picchio, et al
PDF Poster
POSTER
Similar Changes in Metabolic Parameters of Darunavir and Atazanavir, Each Co-administered With Low-dose
Ritonavir in Healthy Volunteers
F Tomaka,, V Seka, T Vangeneugden, J Mrus
PDF Poster
POSTER
Week 48 antiretroviral (ARV) response to darunavir (TMC114)/ritonavir and etravirine (TMC125)
combination in patients with high level viral resistance
M Boffito, A Winston, A Jackson ,et al
PDF Poster

4th IAS Conference on HIV Pathogenesis, Treatment
and Prevention

Comparison of 48-week efficacy and safety of darunavir/ritonavir (DRV/r) with lopinavir/ritonavir (LPV/r)
in LPV/r-naïve, treatment-experienced patients: a randomised, controlled phase III trial (TITAN)
Valdez-Madruga J, Berger D, McMurchie M, et al
Abstract
POSTER
Effect of baseline and on-treatment mutations on the antiretroviral activity of
darunavir/ritonavir (DRV/r) and lopinavir/ritonavir (LPV/r): results of a randomised,
controlled, phase III study (TITAN)
De Meyer S, De Paepe E, Vangeneugden T, et al
PDF Poster Abstract
POSTER
Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in
individuals with impaired hepatic function
Sekar VJ, Spinosa-Guzman S, De Paepe E, et al
PDF Poster Abstract
POSTER
Lack of pharmacokinetic interaction between ritonavir-boosted GS-9137 (elvitegravir) and
Darunavir/r
Mathias A, Shen G, Enejosa J, et al
PDF Poster Abstract
POSTER
QTc study of darunavir co-administered with low-dose ritonavir in healthy, HIV-negative volunteers
Vangeneugden T, Sekar VJ, Lefebvre E, et al
PDF Poster Abstract
POSTER
Dose selection of darunavir co-administered with low-dose ritonavir in treatment-experienced
HIV-1-infected children and adolescents
Spinosa-Guzman S, Sekar VJ, Van Baelen B, et al
PDF Poster Abstract

POSTER
Pharmacokinetic interaction trial between darunavir in combination with low-dose ritonavir
and didanosine
Sekar VJ, Spinosa-Guzman S, De Paepe E, et al
PDF Poster

Conferences Main Page Main New and Noteworthy Home Page